Novo Nordisk Reveals P-III (REDEFINE 2) Trial data of CagriSema for Weight Loss in Obese/Overweight and T2D Patients
Shots:
- Novo Nordisk has reported P-III (REDEFINE 2) trial data assessing CagriSema (cagrilintide 2.4mg + semaglutide 2.4mg, QW, SC) vs PBO in 1,206 obese/overweight pts (~102Kg) and type 2 diabetes for 68wks., and followed flexible dosing protocol with 61.9% pts reaching highest dose after 68wks.
- Trial met its co-1EPs demonstrated 15.7% superior weight loss vs 3.1%, while 89.7% lost ≥5% of body weight vs 30.3%. However, weight loss was 13.7% vs 3.4% using treatment policy estimand
- Additionally, Novo Nordisk has planned to file CagriSema’s first regulatory submission in Q1’26, with full REDEFINE 1 & 2 data to be presented at 2025 conferences
Ref: Novo Nordisk | Image: Novo Nordisk
Related News:- Novo Nordisk Reveals Interim Data from P-III (FRONTIER3) Trial of Mim8 for Haemophilia A with or without Inhibitors
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Ridhi is an avid secondary researcher who follows trends in the biopharmaceutical and healthcare sectors to curate engaging content for the global audience. She works as a news editor at PharmaShots and loves to read books and explore new destinations.
